Google reported the first confirmed AI-assisted zero-day exploit, raising new concerns about logic flaws, supply chain risk, and containment.

Recursion Pharmaceuticals' AI-based approach has the potential to transform the pharmaceutical industry. However, it is still chasing clinical wins that would demonstrate the power of its strategy.

When I last covered the self-styled TechBio company Recursion Pharmaceuticals, Inc. (RXRX) in early October, I was attempting to find reasons why the company's share price was on the rise, up from ~$4 ...

Microsoft has added official Python support to Aspire 13, expanding the platform beyond .NET and JavaScript for building and running distributed apps. Documented today in a Microsoft DevBlogs post, ...

Andrew covers the biopharma industry, scientific research, and public health across the continent. You can reach Andrew confidentially on Signal at drewqjoseph.71. LONDON — In the year-plus since ...

Recursion Pharmaceuticals uses AI to expedite the laborious process of developing drugs. The company could benefit from industry-wide regulatory changes as well as its own clinical progress. However, ...

June 10 (Reuters) - Recursion Pharmaceuticals (RXRX.O), opens new tab said on Tuesday it would lay off about 20% of its workforce as the biotech company tries to cope with an industry-wide funding ...

Recursion Pharmaceuticals is laying off a fifth of its workforce in connection with a previously announced streamlining of the AI biotech’s pipeline. Shrinking the Salt Lake City-based company’s ...

What will the FDA's move mean for Recursion? The FDA will initially focus on monoclonal antibodies with its initiative to replace animal testing and later expand to other types of drugs. How will the ...